ReviewVascular health and risk management2022
Cardiovascular Disease-Associated Skin Conditions.
Review in Vascular health and risk management, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05989945 (HIDRAdenitis Suppurativa and HEART Disease), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HIDRAdenitis Suppurativa and HEART Disease
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Using a full thickness bioengineered human skin equivalent as a model for radiation biology research.Scientific reports · 2025Article
- Observational
- Perceptions and Management of Pregnancy-Related Skin Changes: A Cross-Sectional Study on Knowledge, Practices, and Use of Skincare Product.Journal of cosmetic dermatology · 2025Article
- Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.Pharmaceutics · 2025Review
- Skin Care Supports Overall Well-Being.Clinical, cosmetic and investigational dermatology · 2025Article
- Article
- Radiation dermatitis in the hairless mouse model mimics human radiation dermatitis.Scientific reports · 2024Article
- Review
- The Degrees of Coronary Heart Disease and the Degrees of New-Onset Blepharitis: A Nationwide Cohort Study.Diagnostics (Basel, Switzerland) · 2024Article
- Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.Dermatology and therapy · 2023Review
- A Catastrophic Biodiversity Loss in the Environment Is Being Replicated on the Skin Microbiome: Is This a Major Contributor to the Chronic Disease Epidemic?Microorganisms · 2023Article
- Blueberry Supplementation and Skin Health.Antioxidants (Basel, Switzerland) · 2023Review
- Article
- New Markers for Cardiovascular Disease in Psoriatic Patients: Preliminary Study on Monocyte Phenotype, ADAMTS7, and mTOR Activity.Metabolites · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to data from the American Heart Association and the World Health Organization, cardiovascular disease (CVD) is the most frequent cause of premature death. Several inflammatory and non-inflammatory skin diseases have been associated with metabolic syndrome and cardiovascular risk (CVR). Here, we classified these conditions into traditionally CVR-associated and those that have been linked to a lesser degree. Psoriasis and hidradenitis suppurativa are commonly associated with CVD, sharing common inflammatory pathways and a higher prevalence of traditional cardiovascular risk factors. Many other diseases could be associated indirectly - with no common pathogenic features with the atheromatous disease - but share a higher prevalence of standard cardiovascular risk and chronic inflammatory state. This review aims to highlight the associated cardiovascular risk that exists for some dermatologic diseases and sensitize cardiologists, dermatologists, and first care providers to implement risk factor control promptly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.